SCH-58235

Phase 3Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

SCH-58235 is one of 3 small molecule programs targeting Sitosterolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SitosterolemiaActive, not recruiting

SitosterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Sitosterolemia

#DrugCompanyPhaseTrials

MK0653, Ezetimibe

OOrganon and Co

Phase 3

3 2

SCH-58235

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 3

2 3

Zetia

OOrganon and Co

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sitosterolemia2 trials

Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00099996·3 enrolled

SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00045812·5 enrolled

Interaction1 trial

Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED)

Completed·OOrganon and Co·Phase 1·NCT00653913·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SCH-58235. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCH-58235 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCH-58235. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

SCH-58235

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sitosterolemia2 trials

Interaction1 trial

References

Drug Info

Quick Facts

Related News